PHASQ — PhaseBio Pharmaceuticals Balance Sheet
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$3.73m
- $10.83m
Annual balance sheet for PhaseBio Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 13.4 | 61 | 74 | 28.1 | 41.8 |
Net Total Receivables | — | 0.233 | 1.23 | 0 | — |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 13.7 | 62.6 | 78.8 | 40.1 | 48.8 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.302 | 0.355 | 3.64 | 10.2 | 11.7 |
Other Long Term Assets | |||||
Total Assets | 14.1 | 63 | 82.5 | 50.4 | 60.5 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 17.6 | 4.58 | 8.48 | 15 | 27.9 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 21.9 | 12.1 | 22.5 | 75.6 | 154 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Total Equity | -7.78 | 50.9 | 60 | -25.2 | -93 |
Total Liabilities & Shareholders' Equity | 14.1 | 63 | 82.5 | 50.4 | 60.5 |
Total Common Shares Outstanding |